Cargando…

Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study

BACKGROUND: Prediction of diagnosis of ventilator-associated pneumonia (VAP) remains difficult. Our aim was to assess the value of biomarker kinetics in VAP prediction. METHODS: We performed a prospective, multicenter, observational study to evaluate predictive accuracy of biomarker kinetics, namely...

Descripción completa

Detalles Bibliográficos
Autores principales: Póvoa, Pedro, Martin-Loeches, Ignacio, Ramirez, Paula, Bos, Lieuwe D., Esperatti, Mariano, Silvestre, Joana, Gili, Gisela, Goma, Gema, Berlanga, Eugenio, Espasa, Mateu, Gonçalves, Elsa, Torres, Antoni, Artigas, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Paris 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830786/
https://www.ncbi.nlm.nih.gov/pubmed/27076187
http://dx.doi.org/10.1186/s13613-016-0134-8
_version_ 1782426947390799872
author Póvoa, Pedro
Martin-Loeches, Ignacio
Ramirez, Paula
Bos, Lieuwe D.
Esperatti, Mariano
Silvestre, Joana
Gili, Gisela
Goma, Gema
Berlanga, Eugenio
Espasa, Mateu
Gonçalves, Elsa
Torres, Antoni
Artigas, Antonio
author_facet Póvoa, Pedro
Martin-Loeches, Ignacio
Ramirez, Paula
Bos, Lieuwe D.
Esperatti, Mariano
Silvestre, Joana
Gili, Gisela
Goma, Gema
Berlanga, Eugenio
Espasa, Mateu
Gonçalves, Elsa
Torres, Antoni
Artigas, Antonio
author_sort Póvoa, Pedro
collection PubMed
description BACKGROUND: Prediction of diagnosis of ventilator-associated pneumonia (VAP) remains difficult. Our aim was to assess the value of biomarker kinetics in VAP prediction. METHODS: We performed a prospective, multicenter, observational study to evaluate predictive accuracy of biomarker kinetics, namely C-reactive protein (CRP), procalcitonin (PCT), mid-region fragment of pro-adrenomedullin (MR-proADM), for VAP management in 211 patients receiving mechanical ventilation for >72 h. For the present analysis, we assessed all (N = 138) mechanically ventilated patients without an infection at admission. The kinetics of each variable, from day 1 to day 6 of mechanical ventilation, was assessed with each variable’s slopes (rate of biomarker change per day), highest level and maximum amplitude of variation (Δ(max)). RESULTS: A total of 35 patients (25.4 %) developed a VAP and were compared with 70 non-infected controls (50.7 %). We excluded 33 patients (23.9 %) who developed a non-VAP nosocomial infection. Among the studied biomarkers, CRP and CRP ratio showed the best performance in VAP prediction. The slope of CRP change over time (adjusted odds ratio [aOR] 1.624, confidence interval [CI](95%) [1.206, 2.189], p = 0.001), the highest CRP ratio concentration (aOR 1.202, CI(95%) [1.061, 1.363], p = 0.004) and Δ(max) CRP (aOR 1.139, CI(95%) [1.039, 1.248], p = 0.006), during the first 6 days of mechanical ventilation, were all significantly associated with VAP development. Both PCT and MR-proADM showed a poor predictive performance as well as temperature and white cell count. CONCLUSIONS: Our results suggest that in patients under mechanical ventilation, daily CRP monitoring was useful in VAP prediction. Trial registration NCT02078999 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13613-016-0134-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4830786
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Paris
record_format MEDLINE/PubMed
spelling pubmed-48307862016-04-26 Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study Póvoa, Pedro Martin-Loeches, Ignacio Ramirez, Paula Bos, Lieuwe D. Esperatti, Mariano Silvestre, Joana Gili, Gisela Goma, Gema Berlanga, Eugenio Espasa, Mateu Gonçalves, Elsa Torres, Antoni Artigas, Antonio Ann Intensive Care Research BACKGROUND: Prediction of diagnosis of ventilator-associated pneumonia (VAP) remains difficult. Our aim was to assess the value of biomarker kinetics in VAP prediction. METHODS: We performed a prospective, multicenter, observational study to evaluate predictive accuracy of biomarker kinetics, namely C-reactive protein (CRP), procalcitonin (PCT), mid-region fragment of pro-adrenomedullin (MR-proADM), for VAP management in 211 patients receiving mechanical ventilation for >72 h. For the present analysis, we assessed all (N = 138) mechanically ventilated patients without an infection at admission. The kinetics of each variable, from day 1 to day 6 of mechanical ventilation, was assessed with each variable’s slopes (rate of biomarker change per day), highest level and maximum amplitude of variation (Δ(max)). RESULTS: A total of 35 patients (25.4 %) developed a VAP and were compared with 70 non-infected controls (50.7 %). We excluded 33 patients (23.9 %) who developed a non-VAP nosocomial infection. Among the studied biomarkers, CRP and CRP ratio showed the best performance in VAP prediction. The slope of CRP change over time (adjusted odds ratio [aOR] 1.624, confidence interval [CI](95%) [1.206, 2.189], p = 0.001), the highest CRP ratio concentration (aOR 1.202, CI(95%) [1.061, 1.363], p = 0.004) and Δ(max) CRP (aOR 1.139, CI(95%) [1.039, 1.248], p = 0.006), during the first 6 days of mechanical ventilation, were all significantly associated with VAP development. Both PCT and MR-proADM showed a poor predictive performance as well as temperature and white cell count. CONCLUSIONS: Our results suggest that in patients under mechanical ventilation, daily CRP monitoring was useful in VAP prediction. Trial registration NCT02078999 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13613-016-0134-8) contains supplementary material, which is available to authorized users. Springer Paris 2016-04-14 /pmc/articles/PMC4830786/ /pubmed/27076187 http://dx.doi.org/10.1186/s13613-016-0134-8 Text en © Póvoa et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Póvoa, Pedro
Martin-Loeches, Ignacio
Ramirez, Paula
Bos, Lieuwe D.
Esperatti, Mariano
Silvestre, Joana
Gili, Gisela
Goma, Gema
Berlanga, Eugenio
Espasa, Mateu
Gonçalves, Elsa
Torres, Antoni
Artigas, Antonio
Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study
title Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study
title_full Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study
title_fullStr Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study
title_full_unstemmed Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study
title_short Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study
title_sort biomarker kinetics in the prediction of vap diagnosis: results from the biovap study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830786/
https://www.ncbi.nlm.nih.gov/pubmed/27076187
http://dx.doi.org/10.1186/s13613-016-0134-8
work_keys_str_mv AT povoapedro biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy
AT martinloechesignacio biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy
AT ramirezpaula biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy
AT boslieuwed biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy
AT esperattimariano biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy
AT silvestrejoana biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy
AT giligisela biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy
AT gomagema biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy
AT berlangaeugenio biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy
AT espasamateu biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy
AT goncalveselsa biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy
AT torresantoni biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy
AT artigasantonio biomarkerkineticsinthepredictionofvapdiagnosisresultsfromthebiovapstudy